Goodsurance

Drug prices & Part D

Face-to-Face Drug Price Talks Between Medicare and Manufacturers Close Today on 15 High-Cost Drugs

September 11 is the statutory deadline for in-person and virtual negotiation meetings in Medicare's third drug price negotiation cycle. Written offers are next, with a final CMS offer due September 30 and manufacturer responses due by November 1.

By the Goodsurance editorial teamSeptember 11, 2026

Today is the last day CMS can hold in-person or virtual meetings with drug manufacturers in the third cycle of the Medicare Drug Price Negotiation Program. After today, the parties may only communicate through written offers and responses.

The third cycle covers 15 drugs, including the first medications payable under Medicare Part B ever selected for the program. Negotiations occur throughout 2026, and any agreed prices would take effect January 1, 2028.

Today is the last day Medicare and drug companies can meet face-to-face on prices for 15 high-cost drugs. Written offers follow, with a CMS deadline of September 30.

Under the timeline CMS set in its final guidance for the third cycle, CMS sent each manufacturer an initial offer no later than June 1, 2026. If a manufacturer submitted a counteroffer, CMS could invite up to two additional face-to-face or virtual meetings. That window closes today.

CMS must now issue a final written offer on each drug no later than September 30, 2026. Manufacturers then have until November 1 to accept or decline. A manufacturer that declines faces an escalating excise tax on affected drugs or must withdraw those products from Medicare and Medicaid.

All 15 drug companies whose products were selected for the third cycle chose to participate in the program, according to CMS. If agreements are reached, CMS is expected to publish the negotiated maximum fair prices after the November 1 deadline. Those prices would reduce out-of-pocket costs for beneficiaries starting in 2028.

In plain words

Medicare has a program to lower the price of certain expensive drugs. Today is the last day Medicare can meet in person or by video with drug companies to talk about those prices. They are working on prices for 15 drugs. After today, they can only send each other written messages. Medicare must send its final price offer by September 30. Drug companies then have until November 1 to say yes or no. If they say yes, the new lower prices start on January 1, 2028. Lower prices could mean lower costs for people with Medicare who take those drugs.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Study: Medicare Drug Price Negotiations Cut Costs for Most Enrollees, but Not for Those Already Hitting the Annual Spending Limit

A research letter in Annals of Internal Medicine finds that patients on six of the first ten negotiated Part D drugs saw out-of-pocket costs fall 26 to 49 percent, while patients on the three highest-priced negotiated drugs saw no additional benefit because they were already reaching the annual cap.

October 24, 2026

Drug prices & Part D

A Customs Rule That Would Have Complicated Drug Orders From Canada Is Delayed Three Months

A new paperwork and bonding requirement for international mail containing medications was set to take effect today but was pushed back to January 20, 2027, preserving a cost-saving pathway that many Medicare beneficiaries and other older adults have come to rely on.

October 22, 2026

Drug prices & Part D

CMS Proposes Eliminating the 1-Dollar Generic Drug Copay for the Lowest-Income Medicare Dual Enrollees

A proposed rule published today in the Federal Register would bring the Part D generic drug copayment to zero for full-benefit dual eligible individuals at or below the Federal Poverty Level, starting in 2028.

October 20, 2026

Drug prices & Part D

Drug Maker Agrees to Pay 4 Million Dollars for Billing Medicare Part D for an Eye Drop That Had Gone Over the Counter

Somerset Lifesciences continued labeling a generic antihistamine eye drop as prescription-only for more than three years after its brand equivalent became available without a prescription, causing Medicare to pay pharmacy claims for a drug the program does not cover.

October 19, 2026

Drug prices & Part D

CMS Proposes PBM Transparency Rules and Provider Directory Accuracy Standards for Medicare in 2028

A proposed rule published October 16 would require pharmacy benefit managers in Part D to disclose earnings and manufacturer deals to Medicare, require Medicare Advantage plans to publicly score their own provider directories, and cut generic drug copays to zero for the lowest-income dual-eligible enrollees.

October 17, 2026

Drug prices & Part D

Over 2 Million Enrollees in AARP-Branded Medicare Drug Plans Could Pay at Least 50 Dollars More Per Month in 2027 If They Do Not Switch

A KFF analysis found that AARP Medicare Rx Preferred monthly premiums are rising by at least 50 dollars in every state for 2027, with increases topping 100 dollars per month in four states, a separate finding from the same report that flagged the disappearance of zero-premium plans and one that lands two days before open enrollment opens October 15.

October 13, 2026